Adalimumab for the treatment of psoriatic arthritis.

about

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

P2860

Q37786627-7FDDEC7F-4C56-4FF1-9AEE-91C5F20C6389 Q38150903-A1130FDD-7259-48CF-8DEA-8825DE52454B

P2860

Adalimumab for the treatment of psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q52903765

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Adalimumab for the treatment of psoriatic arthritis.

@en

Adalimumab for the treatment of psoriatic arthritis.

@nl

type

Item

label

Adalimumab for the treatment of psoriatic arthritis.

@en

Adalimumab for the treatment of psoriatic arthritis.

@nl

prefLabel

Adalimumab for the treatment of psoriatic arthritis.

@en

Adalimumab for the treatment of psoriatic arthritis.

@nl

P1476

Adalimumab for the treatment of psoriatic arthritis.

@en

P2093

Martin Rudwaleit

http://www.w3.org/2001/XMLSchema#string

P2860

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

Treatment recommendations for psoriatic arthritis.

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.

Adalimumab for the treatment of ankylosing spondylitis.

P304

671-681

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.09.50

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Denis Poddubnyy

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20477690

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

Adalimumab for the treatment of psoriatic arthritis.

about

P2860

P2860

Adalimumab for the treatment of psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921